
    
      Design: 90 patients will be selected to a prospective, randomized and double-blinded study.
      They will be assigned to two groups: A) 45 patients, treated with OC (oral contraceptive) and
      metformin 1500mg/ day. B) 45 patients, treated with OC and placebo. The length of treatment
      was six months.

      Inclusion criteria: patients until 19 years-old, at least 2 years after menarche, with
      Polycystic Ovary Syndrome based on Rotterdan criterion. Exclusion criteria: patients with
      Diabetes Mellitus, hypertension, hyperprolactinemia, adrenal enzymatic deficiency, Cushing
      syndrome, thyroidopathy, renal or hepatic disfunction, use of OC or insulin-sensitising drugs
      in the last 90 days before, pregnancy, androgen tumors, hormonal-sensitive tumors in the
      past, contra-indication to the medications used in the study.

      Clinical parameters included are weight and height (for BMI), waist to hip ratio, habits like
      smoking or drinking, drug addiction, blood pressure measurement, hirsutism and acne.

      Laboratorial parameters included are TSH, free T4, prolactin, FSH, LH, estradiol, total
      testosterone, androstenedione, s-DHEA, 17-OH progesterone, SHBG, free androgen index, fasting
      glucose and insulin, total cholesterol and fractions, triglycerides, creatinin, TGO, TGP, CK,
      PAI-1, fibrinogen, melatonin.

      Patients will be evaluated using these parameters in the beginning, 1, 3 and 6 months after
      use of the drugs.
    
  